ORIENT BIO Inc.
Korea ExchangeTotal Valuation
ORIENT BIO Inc. carries a market capitalization of 54.31B, placing it among publicly traded companies globally. Its enterprise value stands at 37.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 54.31B |
| Enterprise Value | 37.70B |
Share Statistics
ORIENT BIO Inc. currently has 59.29M shares outstanding.
| Shares Outstanding | 59.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.30, and the price-to-book ratio stands at 1.17.
| PE Ratio | N/A |
| PS Ratio | 2.30 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.00 |
| P/FCF Ratio | 14.75 |
| P/OCF Ratio | 26.40 |
Enterprise Valuation
| EV / Sales | 1.27 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 7.90 |
Financial Position
ORIENT BIO Inc. maintains a current ratio of 7.82, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.82, indicating elevated leverage, while an interest coverage ratio of -32.18 demonstrates limited ability to service its debt obligations.
| Current Ratio | 7.82 |
| Quick Ratio | 5.83 |
| Debt / Equity | 2.82 |
| Debt / EBITDA | -0.47 |
| Interest Coverage | -32.18 |
Financial Efficiency
| Return on Equity (ROE) | -7.56 |
| Return on Assets (ROA) | -5.49 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 7.40 |
Stock Price Statistics
ORIENT BIO Inc.'s stock has declined approximately -41.35723% over the past 52 weeks. The 50-day moving average sits at 954.86, while the 200-day moving average is 1,112.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | -41.35723% |
| 50-Day Moving Average | 954.86 |
| 200-Day Moving Average | 1,112.71 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ORIENT BIO Inc. generated 29.75B in revenue and converted that into -4.57B in net income, yielding earnings per share of -77.03. EBITDA reached -4.13B, while operating income came in at -4.13B.
| Revenue | 29.75B |
| Gross Profit | 5.18B |
| Operating Income | -4.13B |
| Pretax Income | -4.57B |
| Net Income | -4.57B |
| EBITDA | -4.13B |
| EBIT | -4.13B |
| Earnings Per Share (EPS) | -77.03 |
Balance Sheet
ORIENT BIO Inc. holds 32.77B in cash and equivalents against 1.94B in total debt, resulting in a net debt position of -5.83B. Total book value stands at 58.77B, with working capital of 38.35B providing operational flexibility.
| Cash & Cash Equivalents | 32.77B |
| Total Debt | 1.94B |
| Net Debt | -5.83B |
| Equity (Book Value) | 58.77B |
| Book Value Per Share | 991.40 |
| Working Capital | 38.35B |
Cash Flow
ORIENT BIO Inc. produced 2.60B in operating cash flow over the past twelve months. After subtracting -2.05B in capital expenditures, free cash flow totaled 547.86M - equivalent to 9.24 per share.
| Operating Cash Flow | 2.60B |
| Capital Expenditures | -2.05B |
| Free Cash Flow | 547.86M |
| FCF Per Share | 9.24 |
Margins
ORIENT BIO Inc. operates with a gross margin of 17.42, reflecting its pricing power and cost economics. The operating margin of -13.89 and net profit margin of -15.35 provide insight into operational efficiency.
| Gross Margin | 17.42 |
| Operating Margin | -13.89 |
| Pretax Margin | -15.35 |
| Profit Margin | -15.35 |
| EBITDA Margin | -13.89 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 1.00 |
| FCF Yield | 6.78 |
Stock Splits
ORIENT BIO Inc.'s most recent stock split took place on June 9, 2026 with a 2:1 split ratio.
| Last Split Date | 6/9/2026 |
| Split Ratio | 2:1 |
Scores
ORIENT BIO Inc. posts an Altman Z-Score of 3.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.90 |